Carna Biosciences, Inc.
- Biotech or pharma, therapeutic R&D
Carna Biosciences is a clinical-stage company focused on discovering and developing small molecule drugs targeting oncology and autoimmune diseases. Carna’s programs include a non-covalent BTK inhibitor for allergic diseases, a potential first-in-class STING antagonist for immune disorders, a next-generation wild & pan-mutant BTK inhibitor for CLL, and a potential first-in-class CDC7 inhibitor for cancers.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}